ANNX Logo

Annexon, Inc. (ANNX) 

NASDAQ
Market Cap
$483.4M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
130 of 963
Rank in Industry
89 of 552

Largest Insider Buys in Sector

ANNX Stock Price History Chart

ANNX Stock Performance

About Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Insider Activity of Annexon, Inc.

Over the last 12 months, insiders at Annexon, Inc. have bought $1.15M and sold $381,570 worth of Annexon, Inc. stock.

On average, over the past 5 years, insiders at Annexon, Inc. have bought $14.78M and sold $1.09M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Satter Muneer A () — $6.05M. Carson William H. (director) — $139,517.

The last purchase of 3,200 shares for transaction amount of $17,056 was made by Carson William H. (director) on 2024‑12‑02.

List of Insider Buy and Sell Transactions, Annexon, Inc.

2024-12-02Purchasedirector
3,200
0.003%
$5.33$17,056-5.60%
2024-10-15SaleEVP & CHIEF INNOVATION OFFICER
5,408
0.0062%
$7.41$40,073-22.75%
2024-10-01Purchasedirector
3,200
0.003%
$5.97$19,104+6.14%
2024-09-19SaleEVP & CHIEF INNOVATION OFFICER
4,500
0.0043%
$7.10$31,950-8.68%
2024-09-12SaleEVP & CHIEF INNOVATION OFFICER
5,500
0.0048%
$6.16$33,880-1.49%
2024-09-05SaleEVP & CHIEF INNOVATION OFFICER
5,500
0.005%
$5.64$31,020+13.06%
2024-09-03Purchasedirector
3,200
0.0031%
$5.48$17,536+19.87%
2024-08-29SaleEVP & CHIEF INNOVATION OFFICER
5,500
0.0052%
$5.95$32,725+7.17%
2024-08-01Purchasedirector
3,200
0.0031%
$6.24$19,968+0.16%
2024-07-15SaleEVP & CHIEF BUSINESS OFFICER
784
0.0011%
$6.02$4,7200.00%
2024-07-15SaleEVP & CHIEF FINANCIAL OFFICER
1,104
0.0016%
$6.03$6,6570.00%
2024-07-15SaleEVP & CHIEF INNOVATION OFFICER
1,106
0.0016%
$6.02$6,6580.00%
2024-07-01Purchasedirector
3,200
0.0038%
$5.00$16,0000.00%
2024-06-03Purchasedirector
3,200
0.0037%
$4.83$15,459+30.57%
2024-05-01Purchasedirector
3,200
0.0035%
$4.68$14,982+22.11%
2024-04-08Purchasedirector
3,200
0.0036%
$6.07$19,411-5.62%
2024-02-20SaleEVP & CHIEF BUSINESS OFFICER
1,951
0.0026%
$5.48$10,691+10.60%
2024-02-20SaleEVP & CHIEF FINANCIAL OFFICER
2,593
0.0035%
$5.53$14,339+10.60%
2024-02-20SaleEVP & CHIEF INNOVATION OFFICER
2,604
0.0035%
$5.51$14,348+10.60%
2024-02-12SalePRESIDENT AND CEO
5,782
0.0076%
$5.54$32,032+5.16%

Insider Historical Profitability

39.7%
Satter Muneer A
7406024
6.9479%
$4.5430<0.0001%
Love DouglasPRESIDENT AND CEO
196121
0.184%
$4.5419+135.71%
Overdorf MichaelEVP & CHIEF BUSINESS OFFICER
94622
0.0888%
$4.5406
Lew JenniferEVP & CHIEF FINANCIAL OFFICER
86468
0.0811%
$4.5419+33.07%
Yednock TedEVP & CHIEF INNOVATION OFFICER
71365
0.067%
$4.54013
Carson William H.director
25600
0.024%
$4.5480
Bain Capital Life Sciences Investors, LLC10 percent owner
5701926
5.3492%
$4.5420+48.92%
Clarus Lifesciences III, L.P.10 percent owner
2730635
2.5617%
$4.5410+33.07%
Flynn James E10 percent owner
808914
0.7589%
$4.5410+33.07%
Keswani SanjayEVP & Chief Medical Officer
0
0%
$4.5401

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$67.2M9.069.37M-3.23%-$2.24M<0.01
Bain Capital Life Sciences Investors Llc$62.4M8.418.7M+7.96%+$4.6M5.02
Alerce Investment Management L P$53.1M7.167.41M0%+$00.62
Bvf Inc Il$50.19M6.767M0%+$00.37
Redmile Group$39.46M5.325.5M0%+$00.4
Point72 Asset Management$36.97M4.985.16MNew+$36.97M0.05
BlackRock$36.16M4.875.04M+51.98%+$12.37M<0.01
Adage Capital Partners Gp L L C$30.97M4.184.32M-13.6%-$4.88M0.06
The Vanguard Group$26.87M3.623.75M+96.38%+$13.19M<0.0001
Logos Global Management Lp$21.87M2.953.05M-38.38%-$13.62M2.36
GMT Capital$18.97M2.562.65M-12.41%-$2.69M0.77
Bellevue Group$15.65M2.112.18MNew+$15.65M0.24
Octagon Capital Advisors LP$14.7M1.982.05M0%+$00.08
Woodline Partners LP$14.34M1.932M+0.03%+$4,366.530.12
Geode Capital Management$10.25M1.381.43M+55%+$3.64M<0.01
Ikarian Capital LLC$10.07M1.361.41M-46.98%-$8.93M1.39
T. Rowe Price$9.49M1.281.32M+10,482.01%+$9.4M<0.01
Millennium Management LLC$9.16M1.241.28M+57.6%+$3.35M0.01
State Street$8.59M1.161.2M+41.58%+$2.52M<0.0001
Polar Capital$7.17M0.971MNew+$7.17M0.04
JPMorgan Chase$6.88M0.93959,648+3,143.7%+$6.67M<0.01
Acadian Asset Management$6.87M0.93957,993+9.61%+$601,899.100.02
Morgan Stanley$6.45M0.87899,513+368.35%+$5.07M<0.0001
Invesco$5.66M0.76789,044+3,524.12%+$5.5M<0.01
Kennedy Capital Management Inc$5.55M0.75774,698-27.98%-$2.16M0.12
Massachusetts Financial Services Co Ma$5.55M0.75773,914-0.52%-$29,067.18<0.01
Schonfeld Group$5.46M0.74761,600+4,380%+$5.34M0.03
Renaissance Technologies$4.81M0.65671,200+38.62%+$1.34M0.01
Deerfield Management$4.19M0.56583,9130%+$00.01
Goldman Sachs$4.04M0.54562,966+97.58%+$1.99M<0.01
Northern Trust$3.98M0.54555,566+51.27%+$1.35M<0.01
Caption Management Llc$3.58M0.48500,000New+$3.58M0.11
Board Of Trustees Of The Leland Stanford Junior University$3.46M0.47482,5500%+$00.3
D. E. Shaw & Co.$2.72M0.37379,254New+$2.72M<0.01
Boothbay Fund Management LLC$2.69M0.36375,276-46.98%-$2.38M0.09
Two Sigma$2.68M0.36373,448+1,304.84%+$2.49M<0.01
Parkman Healthcare Partners Llc$2.49M0.34346,687New+$2.49M0.31
Dimensional Fund Advisors$2.39M0.32333,913+283.6%+$1.77M<0.01
ExodusPoint Capital Management, LP$2.26M0.31315,155-8.1%-$199,241.140.03
Marshall Wace$2.26M0.31315,612New+$2.26M<0.01
Nuveen$2.21M0.3308,058+58.3%+$813,508.62<0.01
Soleus Capital Management, L.P.$2.1M0.28292,400-43.27%-$1.6M0.01
Driehaus Capital Management LLC$00.25258,3140%+$0<0.0001
Citadel Advisors LLC$1.85M0.25258,675-75.54%-$5.73M<0.01
Ubs Oconnor Llc$1.78M0.24248,277-64.17%-$3.19M0.08
Jump Financial Llc$1.51M0.2210,200New+$1.51M0.01
Two Sigma Advisers LP$1.39M0.19194,400+129.25%+$785,832.00<0.01
Charles Schwab$1.3M0.18181,051+46.4%+$411,436.22<0.0001
BNY Mellon$1.3M0.18180,616+34.51%+$332,250.70<0.0001
Bridgeway Capital Management$1.27M0.17177,500-1.11%-$14,340.000.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.